Phase II Study of Bevacizumab Plus CHOP [cyclophosphamide, doxorubicin, vincristine, prednisolone]-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL).

Trial Profile

Phase II Study of Bevacizumab Plus CHOP [cyclophosphamide, doxorubicin, vincristine, prednisolone]-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
    • 18 Apr 2011 Planned End Date changed from 1 Nov 2010 to 1 Jul 2011, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top